The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 06, 2019

Filed:

Feb. 02, 2018
Applicant:

Roche Diabetes Care, Inc., Indianapolis, IN (US);

Inventors:

Steven Bousamra, Carmel, IN (US);

Stefan Weinert, Pendleton, IN (US);

Juergen Rasch-Menges, Schwetzingen, DE;

P. Douglas Walling, Indianapolis, IN (US);

John F. Price, McCordsville, IN (US);

Heino Eikmeier, Lorsch, DE;

Birgit Kraeling, Fussgoenheim, DE;

Karl Werner, Wiesloch, DE;

Ulrich Porsch, Weinheim, DE;

Assignee:

ROCHE DIABETES CARE INC, Indianapolis, IN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61B 5/02 (2006.01); A61B 5/00 (2006.01); A61B 5/145 (2006.01); G06F 19/00 (2018.01); G16H 10/20 (2018.01); G16H 20/17 (2018.01); G16H 80/00 (2018.01); G16H 10/40 (2018.01); A61M 31/00 (2006.01); A61B 5/05 (2006.01); C12Q 1/00 (2006.01);
U.S. Cl.
CPC ...
A61B 5/0002 (2013.01); A61B 5/14532 (2013.01); A61B 5/14546 (2013.01); G06F 19/3418 (2013.01); G06F 19/3456 (2013.01); G16H 10/20 (2018.01); G16H 10/40 (2018.01); G16H 20/17 (2018.01); G16H 80/00 (2018.01); A61B 5/05 (2013.01); A61M 31/00 (2013.01); A61M 2230/201 (2013.01); C12Q 1/006 (2013.01);
Abstract

Embodiments of a testing method for diabetics to optimize their administered insulin dosage comprise collecting sampling sets of biomarker data, each sampling set comprising a sufficient plurality of non-adverse sampling instances and each sampling instance comprising an acceptable biomarker reading at a single point in time recorded upon compliance with adherence criteria, determining a biomarker sampling parameter from each sampling set, comparing the biomarker sampling parameter to a target biomarker range, calculating an insulin adjustment parameter associated with the biomarker sampling parameter if the biomarker sampling parameter falls outside the target biomarker range, adjusting the insulin dosage by the insulin adjustment parameter if the biomarker sampling parameter falls outside the target biomarker range and the insulin dosage does not exceed maximum dosage, and exiting the testing method if the adjusted insulin dosage is optimized. The insulin dosage is optimized when biomarker sampling parameters fall within the target biomarker range.


Find Patent Forward Citations

Loading…